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Abstract: 
Colorectal cancer  now a days  most common disease in the world many strategies have been under investigated for 
the treatment of colorectal cancer. Colorectal cancer undergoes metastasis and genes responsible for tumor 
suppressor genes. B catenin genes inhibition involves in the cancer. epithelial cells transformed in to the oncogenes. 
Mutation in the WNT pathway leading to the formation of lesion and these polyps leads in the formation of mutation 
in the epithelial cells. TCF family is the main predominant in the colorectal cancer. TCF 4 is the main precursor of 
this family. while TCF1 is the main dominant negative key precursor of this family. 
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INTRODUCTION: 
Colorectal cancer disease is the deadly disease 
occurring in the world. Prevalence   of this type of 
cancer increases with the increasing of age. [1] This 
type of cancer is related with lymph node sometimes it 
may not be related to it. [2] Colorectal cancer is also 
related to the HNPCC syndrome, study show that it is 
autosomal dominant pattern, hereditary  cancer 
syndrome can be diagnosed by the presence of familial 
adenomateous polyposis . 
 
Immunological problems: 
Serum albumin is normally functioning. Ornithine 
decarboxylase activity is normal. Colorectal cancer 
undergoes metastasis and genes responsible for tumor 
suppressor genes [3] B catenin    inhibition involves in 
the  cancer. Epithelial cells transformed in to the 
oncogenes mutation in the WNT pathway leading to 
the formation of lesion and these polyps leads in the 
formation of mutation in the epithelial cells. [4] 
 
genes family involves in the colorectal cancer: 
TCF family is the main predominant in the colorectal 
cancer. [3] TCF 4 is the main precursor of this family 
while TCF1 is the main dominant negative key 
precursor of this family. [5] Adenoma size increase in 
this type of cancer leading to the apoptosis. [6] 
Constant use of aspirin leads to the increase rate of 
colorectal cancer. cyclooxygenase cycle involves in 
the tumour formation its level increases up too many   
leading to the adenoma. cyclooxygenase type 2 
involves in the cell formation of tumour such as in 
colorectal carcinogenesis formation. [7] Cancer 
forming tumors   have   glycolysis cycle depends on 
oxygen more taking of ATP. [8] Tumor signal results 
in the progress of   solid tumour response. [9] Disease    
regulation, study shows that, treatment was observe  
and patients are giving off treatment. [10] Patients of 
colorectal cancer are   assigned to different therapies 
and  bevacizumab- treatment therapy is one of these 
therapies. Patients who are taking these effective 
therapies are discontinue with  the chemotherapy 
treatment   because to show the effect of current 
therapy. [11] The primary results show the survival 
rate. There was no similarty ,  Secondary results  
measures their standard living such a way of living 
which food they take, and their standard living . 
Patients  which are giving the therapy  they also gone 
with the process of analyzing, data was generated  to 
show the survival rate related to this therapy.  Survival 
rate  was  recording  by  the time from randomization 
study  to decline rate  or death during the study, the  
analyses record the result by the therapy after a month 
survival records are analysed with the death rate  for 
different therapies.  
MATERIALS AND METHODS: 
 
Table 1: Questionnaire to evaluate awareness about etiology of Colo Rectal Cancer 
Hepatitis A is a  Yes   No 
1. Viral disease   
2. Bacterial disease    
3. Fungal disease   
4. Genetic disease   
5. Metabolic disease   
Ever suffered from Colorectal Cancer   
6. You   
7. Your family    
8. Your relative    
9. Your neighbor   
10. Your friend   
 Colorectal Cancer is transmitted by   
11. Contacts or blood transfusion   
12. From parents to offspring   
 Colorectal Cancer may be treated by    
13. Medicines   
14. Surgery    
15. Do not worry, it  is easily curable   
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Table 1: Questionnaire to evaluate awareness about etiology of Colorectal Cancer 
Colorectal Cancer is a  Yes   No 
1. Viral disease   
2. Bacterial disease    
3. Fungal disease   
4. Genetic disease   
5. Metabolic disease   
 
Table 2: Questionnaire to evaluate views about prevalence of  Colorectal Cancer 
Ever suffered from Colorectal Cancer  Yes   No 
1. You   
2. Your family    
3. Your relative   
4. Your neighbor    
5. Your friend    
 
3: Questionnaire to evaluate views about transmission of Colorectal Cancer 
Colorectal Cancer is transmitted by  Yes   No 
1. Contacts Table or blood transfusion   
2.     
 
Table 4: Questionnaire to evaluate views about Hope for  Colorectal Cancer 
Colorectal Cancer may be treated by  Yes   No 
1. Medicines   
2. Surgery    
3. Do not worry, it  is easily curable   
 
RESULTS:  
Table 5: Awareness about etiology of ColorectalCancer 
Questions            Male Female Total 
Yes No Yes No Yes No 
1. Viral disease 20% 80% 26.6% 73.3% 30% 74% 
2. Bacterial disease  40% 60% 60% 40% 57% 42% 
3. Fungal disease 20% 80% 53.3% 47% 48% 51% 
4. Genetic disease 0% 100% 27% 73.3% 22% 77% 
5. Metabolic disease 0% 100% 33.3% 67% 28% 71% 
DISCUSSION: 
Results shows that people are not much aware about 
this disease. awareness is very important about some 
disease because it brings knowledge for curing this 
disease. It is also very important about awareness of 
chronic disease. This survey is important because this 
give views about disease. This survey consists of 200 
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students 100 are boys and 100 are girls of the 
BAHUDDIN ZAKARIYA UNIVERSITY Multan. 
 
Role of MSI gene: 
The role of MSI to colorectal cancer has been under 
investigated. MSI means microsatellite instability 
results by having mutation during the DNA replication 
and that results in the formation of tumour  and this   
mutated   repetitive sequence  occurs  in genomes. [12] 
  Without disease progress shows  results, records  on 
progression-survival were recorded   during  or later at 
the time of infection. Patients have no  response under 
the influence of characterized fellow program. [11]  
p53 gene results in apoptosis gene p53 expression 
results the cell cycle arrest in the formation of p21 
gene transcriptional depandant on the kinase activity. 
[13] Study shows that b catenin is present in the colon 
cancer cells. [5]  p21 is the main modulator in the cell 
cycle arrest which enhance the cell division of  
colorectal cancer. mesenchymal cells also under goes 
differentiation under the influence of p21, which 
activates the B catenin. [5] 
 
The  process  which  is responsible for colorectal  
cancer formation are not truly understood. 
 
Analyzing of genes involved in colorectal cancer 
formation process of analyzing normal cells with the 
tumour infected cells from patients of cancer, which 
shows and understanding the process of oncogenes. 
Study shows the protein MYC up regulated the process 
of understanding suppression and  metabolically 
global metabolic process of colorectal tumors  by 
enhancing its activity of  metabolic process of  tumour 
cells. Most important of this point conducting study, 
this metabolic reprogramming process of  tumors 
suppression occurred in a specific site or receptor  not 
connected to a  specific  gene mutations site  in a 
colorectal tumors  formation. Some, small- molecular   
biologic  molecule which act as inhibitor  of gene 
MYC required necessary  for the process of  study 
which involves analyses. Study demonstrate the 
knockdown process of  MYC  gene resulting in the 
downstream process of  pyrimidine  process of 
formation of nucleotide base synthesis genes  takes 
part  to the suppression of colorectal tumors cancer 
cells induction and proliferation and intact gene  of 
MYC, and thus pyrimidine formation synthesis 
pathways may  be perfect  targets for colorectal  cancer 
therapy. [14] 
 
Study conducted to show the mutation in KRAS  gene 
shows for no increase in results  panitumumab therapy. 
The study conducted  for a  control test  made  to study 
the presence or absence of  relative  effect of 
panitumumab therapy in KRAS  mutational pathway  
not depends on the significance  of the potential 
presence of  prognostic  and antagonistic pathway give 
result of strongly influence   of KRAS mutations on the 
possible results, enabling us to study conclusion that 
tumors suppression in the  clinical benefit observed in 
the population  of KRAS unselected population was  
perfectly taken  from the KRAS population. Giving  the 
crossover analyses design, conclusions are only 
limited  to the influence  of KRAS mutational. 
Population on tumor and tumor response end points 
Indeed, the patients received panitumumab therapy on 
disease. [15] To characterize and summarize  the  
cancer cell alterations in colorectal tumors, study show  
a  genome wide  based analysis of  samples, analyzing 
exon  sequence, DNA  promoter methylation cells 
number  and messenger RNA and microRNA 
expression. A subset of  samples  under goes  deeply 
to the   whole  gene sequence. 
Colo rectal tumors  carcinomas  cancer   were exactly 
sure to be highly mutated containing  mutation,  some 
of these have  the expected  high marker microsatellite  
instability inaccuracy, [2] related  with high amount of  
methylation and gene sequencing  also affecting the  
somatic cancer cells  related to the  miss   match-repair 
gene sequence and polymerase proof reading a 
mutation  a  mutations. [16]  Not including in  study   
the   mutated cancers,   colon   rectum cancers were 
found to have considerably similar banding   patterns 
of genomic alteration and sequencing.  genes were 
definitely  mutated altered sequence,  and  in addition 
to  a   mutations. [17]  Frequent mutations related to 
cancer   and mutated     copy-number of  KRAS  
mutation   alterations   and  drug- targetable  
amplifications of and newly discovered  cancer has 
been increased. [18]   chromosomal   mutation which 
specifically introduce translocation  process  include 
the  fusion. [19] Study    analyses  suggest the new 
markers  for the suppression of  colorectal carcinoma 
cancer  it is an  important role for gene directed 
towards the   activation  and  suppression related to the 
colorectal cancer. [20] 
Study   shows that   mutated   carcinomas of the colon 
rectum are   distinguishing  at the genomic  sequence 
level. [13] Tumours   from the  colorectum cancer  
were consists of  likely to be highly  methylated and t 
contain   mutation  rates at elevated level  in the tumors 
suppression process. [21]  Study recognized the  
activation of gene responsible for tumors  signaling   
pathway and in turns  inactivating   the signaling  
pathway, resulting in  the increased activity of the   
many pathways which are responsible for the activity 
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of cancer. [21] Although a number of these genes 
could potentially be key players in the development of 
CRC, their actual role in promoting the growth of 
colon tumours remains to be proven. To identify 
relevant target genes that are important in the 
pathogenesis of CRC, we additionally investigated 
whether reducing the levels of these genes in an 
established colon cancer cell line might  
 alter its proliferation either in culture or when 
implanted in nude mice. Such results would be 
consistent with a possible role for these genes in the 
pathogenesis of colon cancer. Thus, it is important to 
consider possible interactions when using combination 
therapies that disrupt the functions of multiple distinct 
genes. 
 Genome  sequencing targets the large number of 
sequence  and proteins which are involves   in the   
pathways of cancer formation process such as cell 
cycle arrest  also specifically  target   the receptor tyro 
kinase. [17] Study shows   the  understanding of   
deadly disease and  identifying  the possible  for 
treatment for colorectal cancer. [18]Disease  progress 
initially   in the phase  of  the analyses. [14] 
Recommendation for early detection of colorectal 
cancer 
Some tests and procedure for both  gender purpose of 
test is to early detect colorectal cancer. 
Table 1  
Test  Sex  Age Frequency 
Sigmoidoscopy 
preferably flexible 
M,F 50 and over 
 
Every 3 to 5  years 
 
Fecal  Occult Blood Test 
 
M,F 40 and over Every year 
Digital rectal  
examination 
 
M,F 18 and over Every year 
Pap test 
 
M,F 40 and over Every year 
Pelvic Examination 
 
M,F 40  and over Every year 
Endometrial Tissue 
Sample 
 
M,F 18 and over Every year 
Breast self-examination F 18 to 50 Every month 
 
CONCLUSION: 
Many genes involving in the formation and signaling 
of cancer and it is the participation of different genes 
in colorectal cancer. [22] 
 
REFERENCES: 
1. Marteau PR, Vrese Md, Cellier 
CJ,Schrezenmeir J, Protection from 
gastrointestinal diseases with the use of 
probiotics–. Am J Clin Nutr, 2001. 73(2):430s-
436s. 
2. Haraldsdottir S, Einarsdottir HM, Smaradottir 
A, Gunnlaugsson A,Halfdanarson T, Colorectal 
cancer-review.DOAJ, 2014. 100(2):75-82. 
3. Fuller R, Probiotics, in Colonic Microbiota, 
Nutrition and Health. 1999, Springer. p. 89-99. 
4. Guillou PJ, Quirke P, Thorpe H, Walker J, 
Jayne DG, Smith AM, Heath RM, Brown 
JM,group MCt, Short-term endpoints of 
conventional versus laparoscopic-assisted 
surgery in patients with colorectal cancer (MRC 
CLASICC trial): multicentre, randomised 
controlled trial. The lancet, 2005. 
365(9472):1718-1726. 
5. Van De Wetering M, Sancho E, Verweij C, De 
Lau W, Oving I, Hurlstone A, Van Der Horn K, 
Batlle E, Coudreuse D,Haramis A-P, The β-
catenin/TCF-4 complex imposes a crypt 
progenitor phenotype on colorectal cancer cells. 
Cell, 2002. 111(2):241-250. 
6. Fuller R, Probiotics: an overview, in Human 
Health. 1994, Springer. p. 63-73. 
IAJPS 2019, 06 (03), 5314-5319                     Abdul Raheem et al                      ISSN 2349-7750 
 
 
w w w . i a j p s . c o m  
 
Page 5319 
7. Tsujii M, Kawano S,DuBois RN, 
Cyclooxygenase-2 expression in human colon 
cancer cells increases metastatic potential. Proc 
Nati Acad Sci, 1997. 94(7):3336-3340. 
8. Forman D,Burley V, Gastric cancer: global 
pattern of the disease and an overview of 
environmental risk factors. Best Pract Res Clin 
Gastroenterol,006. 20(4):633-649. 
9. Fischbach W, Helicobacter pylori and risk of 
gastric cancer and lymphoma. Highlights in Int 
J Gastrointest Cancer, 2005.  
10. de Gramont Ad, Figer A, Seymour M, Homerin 
M, Hmissi A, Cassidy J, Boni C, Cortes-Funes 
H, Cervantes A,Freyer G, Leucovorin and 
fluorouracil with or without oxaliplatin as first-
line treatment in advanced colorectal cancer. J 
Clinc Oncol, 2000. 18(16):2938-2947. 
11. Hurwitz H, Fehrenbacher L, Novotny W, 
Cartwright T, Hainsworth J, Heim W, Berlin J, 
Baron A, Griffing S,Holmgren E, Bevacizumab 
plus irinotecan, fluorouracil, and leucovorin for 
metastatic colorectal cancer. N  Engl J Med, 
2004. 350(23):2335-2342. 
12. Boland CR, Thibodeau SN, Hamilton SR, 
Sidransky D, Eshleman JR, Burt RW, Meltzer 
SJ, Rodriguez-Bigas MA, Fodde R,Ranzani 
GN, A National Cancer Institute Workshop on 
Microsatellite Instability for cancer detection 
and familial predisposition: development of 
international criteria for the determination of 
microsatellite instability in colorectal cancer. 
1998, AACR. 
13. Yu J, Zhang L, Hwang PM, Kinzler 
KW,Vogelstein B, PUMA induces the rapid 
apoptosis of colorectal cancer cells. Mol Cell, 
2001. 7(3):673-682. 
14. Satoh K, Yachida S, Sugimoto M, Oshima M, 
Nakagawa T, Akamoto S, Tabata S, Saitoh K, 
Kato K,Sato S, Global metabolic 
reprogramming of colorectal cancer occurs at 
adenoma stage and is induced by MYC. Proc 
Nati Acad Sci, 2017. 114(37):E7697-E7706. 
15. Brenner H, Rothenbacher D,Arndt V, 
Epidemiology of stomach cancer, in Cancer 
Epidemiology. 2009, Springer. p. 467-477. 
16. Kopp-Hoolihan L, Prophylactic and therapeutic 
uses of probiotics: a review. J Am Diet A, 2001. 
101(2):229-241. 
17. Reid G, Jass J, Sebulsky MT,McCormick JK, 
Potential uses of probiotics in clinical 
practice.CMR, 2003. 16(4):658-672. 
18. Network CGA, Comprehensive molecular 
characterization of human colon and rectal 
cancer. Nature, 2012. 487(7407):330. 
19. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, 
Lynch JF, Lynch PM, Cavalieri RJ,Boland CR, 
Genetics, natural history, tumor spectrum, and 
pathology of hereditary nonpolyposis colorectal 
cancer: an updated review Entero Onco, 1993. 
104(5):1535-1549. 
20. Otles S, Cagindi O,Akcicek E, Probiotics and 
health. APJCP, 2003. 4(4):369-372. 
21. Rothenbacher D,Brenner H, Helicobacter 
pylori and gastric cancer.NLM, 2004. 
126(7):1927. 
22. Levin B,Murphy GP, Revision in American 
Cancer Society recommendations for the 
earlydetection of colorectal cancer. CA:, 1992. 
42(5):296-299. 
